用于完全闭环双激素腹腔内人工胰腺中使用的葡萄糖出现率的估计和预测
IEEE transactions on bio-medical engineering
|August 3, 2023
概括
这项研究开发了一种用于人工胰腺系统的新型食估计器. 该技术准确预测血糖水平 (BGL) 和葡萄糖出现率 (GAR),减少1型糖尿病管理的手动干预.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 控制系统 控制系统
背景情况:
- 完全自动化的人工胰腺系统需要准确的饮食估计和血糖水平 (BGL) 预测.
- 手动的餐点预告和用户干预是当前人工胰腺技术的局限性.
研究的目的:
- 引入一种用于估计葡萄糖出现率 (GAR) 和预测BGL的技术,用于1型糖尿病管理.
- 为了实现完全自动化的人工胰腺,而无需手动的餐点预告.
主要方法:
- 使用移动地平线估计 (MHE) 方法进行GAR估计.
- 将每日GAR模式的先前统计信息纳入MHE成本函数.
- 开发了一个预测方案,使用肠道模型和估计状态来预测GAR,随后通过葡萄糖代谢模型预测BGL.
主要成果:
- 在GAR估计中达到21.8%的平均绝对百分比误差 (MAPE),在BGL预测中达到10.0%的MAPE (已知未来GAR).
- 对于120分钟的预测时间,预测器给出了GAR的18.0%的MAPE和BGL的28.4%的MAPE.
- 在麻醉动物模型中证明了有效性和可靠性.
结论:
- 建议的估计和预测技术是有效和可靠的.
- 这一进步为完全自动化的人工胰腺系统带来了巨大的潜力.
- 该研究有助于减少用户干预,提高1型糖尿病患者的生活质量.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Hypoglycemia and Glucagon
301
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
301
Glucose Homeostasis: Regulation of Blood Glucose
1.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.8K
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358


